The first two authors contributed equally to this work and should be considered as first authors.
Oral Tranexamic Acid Enhances the Efficacy of Low-Fluence 1064-Nm Quality-Switched Neodymium-Doped Yttrium Aluminum Garnet Laser Treatment for Melasma in Koreans: A Randomized, Prospective Trial
Article first published online: 26 DEC 2012
© 2012 by the American Society for Dermatologic Surgery, Inc. Published by Wiley Periodicals, Inc.
Volume 39, Issue 3pt1, pages 435–442, March 2013
How to Cite
Shin, J. U., Park, J., Oh, S. H. and Lee, J. H. (2013), Oral Tranexamic Acid Enhances the Efficacy of Low-Fluence 1064-Nm Quality-Switched Neodymium-Doped Yttrium Aluminum Garnet Laser Treatment for Melasma in Koreans: A Randomized, Prospective Trial. Dermatologic Surgery, 39: 435–442. doi: 10.1111/dsu.12060
The authors have indicated no significant interest with commercial supporters.
- Issue published online: 4 MAR 2013
- Article first published online: 26 DEC 2012
- Hyundai Pharmacy
Tranexamic acid (TA) has recently gained in popularity in the treatment of pigmentary disorders.
To evaluate the clinical efficacy and safety of oral TA combined with low-fluence 1064-nm quality-switched neodymium-doped yttrium aluminum garnet (QSNY) laser for the treatment of melasma.
Materials and methods
Forty-eight patients with melasma were enrolled in the study and subsequently divided into two groups: a combination group and a laser treatment group. All patients were treated with two sessions of low-fluence QSNY laser, and patients in the combination group took 8 weeks of oral TA. Two blinded dermatologists evaluated patients using the Modified Melasma Area and Severity Index (mMASI) and a clinical improvement scale.
Mean mMASI score 4 weeks after the second treatment decreased significantly in both groups from base line. Based on overall clinical improvement, a greater number of patients scored as grade 3 and more in the combination group; no patients were scored as grade 4 in the laser-alone group.
Oral TA may prove a safe and efficient treatment option for melasma in combination with low-fluence QSNY laser therapy.